JP2014528431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014528431A5 JP2014528431A5 JP2014533869A JP2014533869A JP2014528431A5 JP 2014528431 A5 JP2014528431 A5 JP 2014528431A5 JP 2014533869 A JP2014533869 A JP 2014533869A JP 2014533869 A JP2014533869 A JP 2014533869A JP 2014528431 A5 JP2014528431 A5 JP 2014528431A5
- Authority
- JP
- Japan
- Prior art keywords
- sustained
- coating
- release pharmaceutical
- water
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544026P | 2011-10-06 | 2011-10-06 | |
| US61/544,026 | 2011-10-06 | ||
| PCT/EP2012/069541 WO2013050419A1 (en) | 2011-10-06 | 2012-10-03 | Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014528431A JP2014528431A (ja) | 2014-10-27 |
| JP2014528431A5 true JP2014528431A5 (enExample) | 2015-11-12 |
| JP6368242B2 JP6368242B2 (ja) | 2018-08-01 |
Family
ID=46968222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014533869A Expired - Fee Related JP6368242B2 (ja) | 2011-10-06 | 2012-10-03 | ４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20140242162A1 (enExample) |
| EP (1) | EP2763663B1 (enExample) |
| JP (1) | JP6368242B2 (enExample) |
| KR (1) | KR101643219B1 (enExample) |
| CN (1) | CN103874484B (enExample) |
| AR (1) | AR088232A1 (enExample) |
| AU (1) | AU2012320563B2 (enExample) |
| BR (1) | BR112014007902A2 (enExample) |
| CA (1) | CA2850995A1 (enExample) |
| CL (1) | CL2014000844A1 (enExample) |
| CO (1) | CO6930364A2 (enExample) |
| EA (1) | EA025595B1 (enExample) |
| ES (1) | ES2663744T3 (enExample) |
| GT (1) | GT201400062A (enExample) |
| IL (1) | IL231648A0 (enExample) |
| MA (1) | MA35513B1 (enExample) |
| MX (1) | MX2014004166A (enExample) |
| PE (1) | PE20141649A1 (enExample) |
| PH (1) | PH12014500746A1 (enExample) |
| SG (1) | SG11201400730VA (enExample) |
| TN (1) | TN2014000114A1 (enExample) |
| TW (1) | TWI475993B (enExample) |
| WO (1) | WO2013050419A1 (enExample) |
| ZA (1) | ZA201401961B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201503912A (zh) * | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物 |
| JP6678676B2 (ja) | 2014-09-15 | 2020-04-08 | オーファザイム エー／エス | アリモクロモル製剤 |
| AU2016225026A1 (en) | 2015-02-27 | 2017-09-07 | Canopy Growth Corporation | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| WO2016185443A1 (en) | 2015-05-20 | 2016-11-24 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| WO2017018433A1 (ja) * | 2015-07-28 | 2017-02-02 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物及びその製造方法 |
| JP6762158B2 (ja) * | 2015-07-28 | 2020-09-30 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| EP3345601A4 (en) * | 2015-09-03 | 2019-05-15 | Nippon Kayaku Kabushiki Kaisha | PHARMACEUTICAL COMPOSITION CONTAINING RAPAMYCIN OR A DERIVATIVE THEREOF |
| JP6854639B2 (ja) * | 2016-01-06 | 2021-04-07 | 日本化薬株式会社 | ラパマイシン誘導体を含有する医薬組成物及びその製造方法 |
| US12485129B2 (en) | 2016-08-29 | 2025-12-02 | Canopy Growth Corporation | Water soluble compositions comprising purified cannabinoids |
| WO2018044953A1 (en) | 2016-08-29 | 2018-03-08 | Ebbu, LLC | Water soluble compositions comprising purified cannabinoids |
| CA3044355A1 (en) | 2016-11-23 | 2018-05-31 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
| EP3576735A4 (en) * | 2017-02-06 | 2020-07-22 | Intas Pharmaceuticals Limited | PHARMACEUTICAL COMPOSITION OF EVEROLIMUS |
| KR102051806B1 (ko) * | 2018-01-12 | 2019-12-04 | 주식회사 종근당 | 에베로리무스를 포함하는 안정화된 약제학적 제제 |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| EP4125913A4 (en) * | 2020-03-30 | 2023-08-23 | IGIA Pharmaceuticals, Inc. | PEDIATRIC TYROSINE KINASE INHIBITOR FORMULATION |
| WO2022219652A1 (en) * | 2021-04-17 | 2022-10-20 | Bdr Pharmaceuticals International Private Limited | Novel sublingual pharmaceutical formulations for everolimus |
| KR102336007B1 (ko) * | 2021-06-23 | 2021-12-07 | 주식회사 진성이앤지 | 콘크리트용 우레탄계 방수·방식 도막재 및 이를 이용한 방수·방식 도장 공법 |
| WO2023044024A1 (en) * | 2021-09-17 | 2023-03-23 | Novelstar Pharmaceuticals Inc. | Novel ph dependent coating drug delivery system |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| DK2198858T3 (da) * | 1998-03-26 | 2011-10-03 | Astellas Pharma Inc | Præparat med opretholdt frigivelse af en makrolidforbindelse såsom tacrolimus |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| AR045957A1 (es) | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
| GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
| EP1902708A1 (de) * | 2006-09-25 | 2008-03-26 | Losan Pharma GmbH | Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung |
| DK2365802T3 (da) * | 2008-11-11 | 2017-11-13 | Univ Texas | Mikrokapsler af rapamycin og anvendelse til behandling af cancer |
| CN101862297B (zh) * | 2009-04-14 | 2012-07-25 | 上海医药工业研究院 | 一种非水溶性药物的缓释微丸、其缓释口腔崩解片及其制备方法 |
-
2012
- 2012-10-03 EP EP12766990.1A patent/EP2763663B1/en active Active
- 2012-10-03 CA CA2850995A patent/CA2850995A1/en not_active Abandoned
- 2012-10-03 ES ES12766990.1T patent/ES2663744T3/es active Active
- 2012-10-03 PE PE2014000448A patent/PE20141649A1/es not_active Application Discontinuation
- 2012-10-03 CN CN201280049427.XA patent/CN103874484B/zh not_active Expired - Fee Related
- 2012-10-03 PH PH1/2014/500746A patent/PH12014500746A1/en unknown
- 2012-10-03 JP JP2014533869A patent/JP6368242B2/ja not_active Expired - Fee Related
- 2012-10-03 MX MX2014004166A patent/MX2014004166A/es not_active Application Discontinuation
- 2012-10-03 KR KR1020147008751A patent/KR101643219B1/ko not_active Expired - Fee Related
- 2012-10-03 BR BR112014007902A patent/BR112014007902A2/pt not_active IP Right Cessation
- 2012-10-03 US US14/349,166 patent/US20140242162A1/en not_active Abandoned
- 2012-10-03 SG SG11201400730VA patent/SG11201400730VA/en unknown
- 2012-10-03 EA EA201490743A patent/EA025595B1/ru not_active IP Right Cessation
- 2012-10-03 WO PCT/EP2012/069541 patent/WO2013050419A1/en not_active Ceased
- 2012-10-03 AU AU2012320563A patent/AU2012320563B2/en not_active Ceased
- 2012-10-04 AR ARP120103699A patent/AR088232A1/es unknown
- 2012-10-05 TW TW101137004A patent/TWI475993B/zh not_active IP Right Cessation
-
2014
- 2014-03-18 ZA ZA2014/01961A patent/ZA201401961B/en unknown
- 2014-03-18 TN TNP2014000114A patent/TN2014000114A1/en unknown
- 2014-03-20 IL IL231648A patent/IL231648A0/en unknown
- 2014-04-03 MA MA36880A patent/MA35513B1/fr unknown
- 2014-04-04 GT GT201400062A patent/GT201400062A/es unknown
- 2014-04-04 CL CL2014000844A patent/CL2014000844A1/es unknown
- 2014-04-04 CO CO14073134A patent/CO6930364A2/es not_active Application Discontinuation
-
2016
- 2016-11-07 US US15/345,498 patent/US20170049754A1/en not_active Abandoned
-
2018
- 2018-01-24 US US15/879,272 patent/US20180214424A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014528431A5 (enExample) | ||
| JP4656815B2 (ja) | 一日に一回のオキシコドン製剤 | |
| JP5937068B2 (ja) | 転用防止微粒剤および微小錠剤 | |
| JP6325148B2 (ja) | 注意欠陥障害の処置のための方法および組成物 | |
| JP2014505736A5 (enExample) | ||
| ES2582453T3 (es) | Forma farmacéutica oral sólida contra el uso indebido y dotada de un perfil específico de liberación modificada | |
| JP5592902B2 (ja) | 治療薬の徐放性組成物 | |
| HRP20230305T1 (hr) | Pripravci za ileo-jejunalnu dostavu lijeka | |
| CA2488868A1 (en) | Controlled release formulation of lamotrigine | |
| JP2016106078A (ja) | アルコール耐性経口医薬形態 | |
| JP2018517735A5 (enExample) | ||
| JP2006514988A5 (enExample) | ||
| WO2015193788A1 (en) | Formulation for oral administration containing mesalazine | |
| JP2017532363A5 (enExample) | ||
| JP2017536401A5 (enExample) | ||
| JP2014533656A5 (enExample) | ||
| RU2014127884A (ru) | Способы лечения сердечно-сосудистого нарушения | |
| US20190105275A1 (en) | Oral pharmaceutical compositions of mesalazine | |
| JP2014208655A5 (enExample) | ||
| HRP20161340T1 (hr) | Formulacije darunavira | |
| AR109898A1 (es) | Perlas multicapa para uso farmacéutico | |
| AU2015349896A1 (en) | Pharmaceutical bead formulations comprising dimethyl fumarate | |
| RU2014132940A (ru) | Терапия болезни паркинсона с применением комбинации с фиксированными дозами | |
| US20110244050A1 (en) | Pulsed-release sildenafil composition and method for preparing said composition | |
| JP2019513801A5 (enExample) |